Seizure characteristics in epilepsy patients with a primary brain tumor
Journal of Neuro-Oncology · 2026
DOI: 10.1007/s11060-025-05331-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Neuro-Oncology, 2026. Verfasst von Lena Vegh und 2 weiteren Autor:innen. Beteiligte Einrichtung: Gray Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv, Israel. lena.a.vegh@gmail.com. Hauptthemen laut MEDLINE: Brain Neoplasms, Epilepsy, Seizures. Die Arbeit nennt 18 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: Epilepsy is among the most prevalent neurological disorders, with one in 10 people experiencing a seizure in their lifetime. In adults, brain tumors are a common cause. While tumor-control outcomes are well studied, less is known about seizure control in this population. METHODS: We retrospectively reviewed the Clalit Dan–Petah Tikva County database (2000–2019), covering 1.55 million patients. Adults with primary brain tumors and epilepsy were identified by ICD-10 codes. Seizure control and management were assessed through anti-seizure medication (ASM) prescriptions, follow-up care, hospitalizations, and evaluation by specialized epilepsy clinics. RESULTS: Among 1,557,764 individuals, 17,225 (1.1%) adults were diagnosed with a brain tumor, of whom 14.7% (n = 2,532) had secondary epilepsy. Glioma patients had more than double the epilepsy rate (29.2%, n = 878) compared to meningioma (13.1%, n = 1,417). Most epilepsy cases were associated with benign tumors (65.6%, n = 1,661). Overall, 9.7% (n = 1,672) were classified as high-risk for drug-resistant epilepsy (DRE), yet only 0.5% (n = 89) had a formal diagnosis. Of these, just 12 (0.7%) received follow-up at a specialized epilepsy clinic; the remainder were managed by community neurologists, oncologists, neurosurgeons, or primary care physicians. None of the patients with intractable epilepsy underwent evaluation for epilepsy surgery. CONCLUSION: Despite adequate tumor control, many patients with tumor-related epilepsy continue to experience seizures after resection and oncological treatment, due to suboptimal management or intractability. Under-recognition of DRE and low referral rates to specialized epilepsy centers highlight a significant treatment gap. Improved referral pathways and comprehensive evaluations are needed to optimize seizure outcomes in this population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Gray Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv, Israel. lena.a.vegh@gmail.com.
- Department of Neurology, Rabin Medical Center, Petah-Tikva, Israel.
- Department of Neurosurgery, Rabin Medical Center, Petah-Tikva, Israel.
Zitieren
APA
Vegh, L., Benninger, F., & Tamir, I. (2026). Seizure characteristics in epilepsy patients with a primary brain tumor. Journal of Neuro-Oncology. https://doi.org/10.1007/s11060-025-05331-3
Vancouver
Vegh L, Benninger F, Tamir I. Seizure characteristics in epilepsy patients with a primary brain tumor. Journal of Neuro-Oncology. 2026. doi:10.1007/s11060-025-05331-3
BibTeX
@article{Vegh2026,
author = {Vegh, Lena and Benninger, Felix and Tamir, Idit},
title = {Seizure characteristics in epilepsy patients with a primary brain tumor},
journal = {Journal of Neuro-Oncology},
year = {2026},
doi = {10.1007/s11060-025-05331-3}
}
EUVIMED